Testing a new three-drug combination for aggressive lymphoma

This trial is testing a combination of three medications—orelabrutinib, lisaftoclax, and rituximab—for people with mantle cell lymphoma (an aggressive type of blood cancer) that has never been treated before and shows high-risk features. The three drugs work together in different ways to target cancer cells: orelabrutinib blocks a protein that helps cancer grow, lisaftoclax triggers cancer cells to die, and rituximab helps your immune system recognize and attack the cancer. The goal is to see if this combination can help patients with this difficult-to-treat form of lymphoma live longer without their cancer coming back.

Mantle cell lymphoma is often resistant to standard treatments, especially when it has high-risk features like certain genetic changes or aggressive growth patterns. Recent research shows that combining multiple targeted drugs—rather than using chemotherapy alone—may work better for these patients. This trial aims to find out whether this newer three-drug combination is more effective and safer than older treatment approaches.